February 8, 2016
A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on February 5 backed approval for an additional pain indication for Shionogi’s antidepressant Cymbalta (duloxetine) through a rare majority vote, rather than the usual consensus. The Pharmaceutical...read more